Literature DB >> 11305311

Public health. HIV/AIDS treatment for millions.

H P Binswanger1.   

Abstract

Entities:  

Keywords:  Health Care and Public Health

Mesh：

Substances：

Year:  2001        PMID： 11305311     DOI： 10.1126/science.1057504

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


× No keyword cloud information.
  5 in total

1.  Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.

Authors:  Annette Oxenius; David A Price; Huldrych F Günthard; Sara J Dawson; Catherine Fagard; Luc Perrin; Marek Fischer; Rainer Weber; Montserrat Plana; Felipe García; Bernard Hirschel; Angela McLean; Rodney E Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-07       Impact factor: 11.205

2.  Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Authors:  M Dybul; T W Chun; C Yoder; B Hidalgo; M Belson; K Hertogs; B Larder; R L Dewar; C H Fox; C W Hallahan; J S Justement; S A Migueles; J A Metcalf; R T Davey; M Daucher; P Pandya; M Baseler; D J Ward; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

3.  Genetic characterization of rebounding human immunodeficiency virus type 1 in plasma during multiple interruptions of highly active antiretroviral therapy.

Authors:  Mark Dybul; Marybeth Daucher; Mark A Jensen; Claire W Hallahan; Tae-Wook Chun; Michael Belson; Bertha Hidalgo; David C Nickle; Christian Yoder; Julia A Metcalf; Richard T Davey; Linda Ehler; Diane Kress-Rock; Elizabeth Nies-Kraske; Shuying Liu; James I Mullins; Anthony S Fauci
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

4.  Structured Treatment Interruption: Approaches and Risks.

Authors:  Mark Dybul
Journal:  Curr Infect Dis Rep       Date:  2002-04       Impact factor: 3.725

5.  Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Authors:  Hermann Bussmann; C William Wester; Ann Thomas; Vladimir Novitsky; Reginald Okezie; Tanaka Muzenda; Tendani Gaolathe; Ndwapi Ndwapi; Norah Mawoko; Erik Widenfelt; Sikhulile Moyo; Rosemary Musonda; Madisa Mine; Joseph Makhema; Howard Moffat; Max Essex; Victor Degruttola; Richard G Marlink
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.